#Australia #Hyperbaric Therapy #brain cancer #Lismore #Southern Cross University

Innovative Clinical Study on Mild Hyperbaric Oxygen Therapy

A groundbreaking clinical trial is set to unfold in Australia, led by researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG). This study is aimed at evaluating the safety and efficacy of mild hyperbaric oxygen therapy (HBOT) for patients undergoing treatment for high-grade glioma, an aggressive form of brain cancer.

The Need for Innovative Treatment

High-grade glioma is notoriously difficult to treat and is associated with poor prognosis. Traditional treatments include surgery, chemotherapy, and radiotherapy, but their effectiveness can be hindered by the tumor's hypoxic nature—meaning it receives low levels of oxygen. This hypoxia can not only impair the function of treatments such as radiotherapy, which relies on oxygen to destroy cancer cells but can also lead to a more aggressive tumor behavior.

In light of this, the research team is investigating whether delivering oxygen in a controlled, pressurized setting during treatment can enhance both the effectiveness of the oncology treatment and the patient's overall well-being, recovery, and treatment tolerance.

Support from Philanthropy

The project has received considerable backing in the form of a $1 million donation from an anonymous benefactor, which will enable thorough research into this innovative treatment modality. The study is set to be the first of its kind in Australia, but it also holds global significance as the first to combine mild HBOT (operating at about 1.35 ATA, a lower pressure than conventional hyperbaric treatments) with molecular hydrogen in an oncology context.

What is Mild Hyperbaric Oxygen Therapy?

Mild hyperbaric oxygen therapy involves the patient breathing concentrated oxygen while inside a pressurized chamber. This method allows oxygen to dissolve more effectively into the bloodstream, facilitating delivery to tissues that often lack adequate oxygen levels, which is common in solid tumors.

Traditional uses of HBOT in Australia have primarily focused on conditions resulting from past radiation injuries, such as osteoradionecrosis and soft-tissue damages. Yet, its role in ongoing cancer treatments has not been widely explored or implemented, creating a significant gap the current study seeks to address.

A Shift in Perspective

This research marks a pivotal shift from viewing HBOT solely as a rehabilitation tool post-treatment to a potential supportive therapy used actively during treatment. Past studies have generally utilized traditional HBOT at higher pressures (2-3 ATA), which may differ in safety and tolerability compared to the lower-pressure regime planned for this trial.

Evidence from Other Medical Domains

Encouraging outcomes from previous studies utilizing mild HBOT in non-cancer contexts—like improving conditions associated with poor circulation, sports injuries, post-concussion syndromes, and disorders such as Parkinson's disease—provide a hopeful backdrop for the study.

Professor Jon Wardle, the Foundation Director at the National Centre for Naturopathic Medicine at Southern Cross University, expressed enthusiasm about the prospects of this study. He stated, "As interest in therapies such as hyperbaric oxygen continues to grow, it is essential that we generate high-quality evidence to inform clinical decision-making. Partnering with MIOG allows us to investigate HBOT in a real-world clinical environment while maintaining strong academic and research standards."

The outcomes of this study could pave the way for new strategies in managing aggressive brain cancers, enhancing not only the effectiveness of traditional treatments but also the quality of life for patients during their battle against this formidable disease.

In a time where alternative and integrative therapies are gaining traction, this study could be a landmark moment in the landscape of oncological care, combining research innovation with practical application to touch lives positively and potentially reshape treatment paradigms for brain cancer patients.